Key result
Intravenous administration of deltorphin-II prior to reperfusion in old rats with metabolic syndrome reduced myocardial infarct size to 27% of the risk zone compared to 45% in controls.
Why the study?
The discovery of new pharmacological agents for myocardial protection during reperfusion injury is an urgent goal, leading researchers to evaluate whether the delta-2 opioid receptor agonist deltorphin-II protects the myocardium prior to reperfusion in old rats with diet-induced metabolic syndrome.
Does deltorphin-II reduce infarct size in old rats with diet-induced metabolic syndrome undergoing ischemia-reperfusion?
Does deltorphin-II reduce infarct size in old rats with diet-induced metabolic syndrome undergoing ischemia-reperfusion?
Absolute Event Rate: 27% vs 45%
Deltorphin-II demonstrates cardioprotective efficacy by significantly reducing infarct size in a rat model of aging and metabolic syndrome.
Deltorphin-II pretreatment limited infarct size in aged rats with metabolic syndrome; hypothesis-generating and should not yet change practice.
Background. The discovery of new pharmacological agents for myocardial protection during reperfusion injury is an urgent goal of modern physiology and pharmacology. The aim of the study. To identify the potential for protecting the myocardium from reperfusion injury by administering the delta-2 opioid receptor agonist deltorphin-II prior to reperfusion in old rats with diet-induced metabolic syndrome. Materials and methods. The study was performed on Wistar rats aged 60 days (young rats) and 450 days (old rats) before the onset of a study. Metabolic syndrome (MetS) was modeled for 84 days with a high-carbohydrate high-fat diet (16 % protein, 21 % fat, 46 % carbohydrate) with the replacement of drinking water with 20 % fructose solution. Myocardial infarction was performed by 45-min coronary occlusion followed by 120-min reperfusion; the size of the area of the necrotic myocardium was determined relative to the size of the hypoperfusion zone. The delta-2 opioid receptor agonist deltorphin-II was administered once intravenously 5 minutes before the end of ischemia. Results. It was found that coronary occlusion and subsequent reperfusion both in groups of young and old rats led to the formation of myocardial infarction (necrosis), the size of which was 45 % of the size of the risk zone. Administration of deltorphin-II in old rats led to a limitation of infarct size to 30 % of the size of the risk zone, i. e. 1.7-fold. The use of deltorphin-II in old rats with MetS contributed to a decrease in infarct size to 27 % of the size of the risk zone (1.5 times). The obtained results demonstrate the cardioprotective efficacy of the delta-2 opioid receptor agonist deltorphin-II in aging and metabolic syndrome in rats. Conclusions. These data may serve as a basis for conducting preclinical studies of deltorphin-II as a drug for treatment of acute myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Naryzhnaya et al. (2022) studied Myocardial infarction and metabolic syndrome. Deltorphin-II vs. Control (no deltorphin-II) was evaluated on Size of the area of the necrotic myocardium relative to the size of the hypoperfusion (risk) zone. Intravenous administration of deltorphin-II prior to reperfusion in old rats with metabolic syndrome reduced myocardial infarct size to 27% of the risk zone compared to 45% in controls.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: